ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...

GuruFocus.com
01 Apr
  • Net Product Revenue (Q4 2024): $16.4 million, compared to $16.6 million in Q4 2023.
  • Net Product Revenue (Full Year 2024): $69.3 million, compared to $69.1 million in 2023.
  • Operating Expenses Reduction: Decreased by 13% year-over-year on a non-GAAP basis.
  • Net Loss (Q4 2024): $30.7 million or $0.29 per share, compared to $85 million or $1.03 per share in Q4 2023.
  • Net Loss (Full Year 2024): $157.8 million or $1.62 per share, compared to $240.1 million or $2.94 per share in 2023.
  • Adjusted Net Loss (Q4 2024): $26.5 million or $0.25 per share, compared to $79.5 million or $0.97 per share in Q4 2023.
  • Adjusted Net Loss (Full Year 2024): $111.4 million or $1.15 per share, compared to $185.7 million or $2.27 per share in 2023.
  • Cash and Cash Equivalents (End of 2024): $251 million, expected to fund operations into the second half of 2026.
  • Warning! GuruFocus has detected 5 Warning Signs with ADCT.

Release Date: March 27, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • ADC Therapeutics SA (NYSE:ADCT) achieved commercial brand profitability with ZYNLONTA in the competitive third-line plus DLBCL space.
  • The company completed enrollment in the pivotal Phase 3 LOTIS-5 trial and reported promising initial data from the LOTIS-7 trial.
  • ADCT achieved a double-digit reduction in operating expenses for the second consecutive year, strengthening its financial position.
  • The company ended 2024 with $251 million in cash and cash equivalents, providing a cash runway into the second half of 2026.
  • Promising Phase 2 data from investigator-initiated trials in indolent lymphomas suggest potential for significant market opportunities.

Negative Points

  • ZYNLONTA's net product revenues remained flat year-over-year, indicating challenges in revenue growth.
  • The competitive landscape in the third-line plus DLBCL market remains intense, with new entrants like Pfizer's ADCETRIS posing potential challenges.
  • Despite progress, the company reported a net loss of $157.8 million for the full year 2024.
  • The market for ZYNLONTA in indolent lymphomas is estimated to be $100 million to $200 million, which may be considered modest.
  • The company faces uncertainty regarding the timing and outcome of regulatory approvals and compendia listings for its pipeline products.

Q & A Highlights

Q: Can you provide details on the LOTIS-7 update expected in Q2? A: We haven't disclosed the specific forum or exact timing within Q2 for sharing the LOTIS-7 data. However, we are on track to enroll 40 patients in the dose expansion in the second quarter. We will share safety and efficacy data on a portion of those patients in Q2 and data on all 40 patients in the second half of the year. - Ameet Mallik, CEO

Q: How do you view the impact of Pfizer's ADCETRIS approval on ZYNLONTA's market position? A: The approval of ADCETRIS plus R-squared in the third-line setting is expected to have limited impact. Physicians have multiple options, and based on our market research, any use of ADCETRIS is likely to replace older regimens like R-squared or R-based chemo in the third-line plus DLBCL setting. - Ameet Mallik, CEO

Q: What is the market opportunity for ZYNLONTA in indolent lymphomas? A: Based on compelling data presented in marginal zone lymphoma and follicular lymphoma, we believe the peak opportunity for ZYNLONTA in indolent lymphomas will be in the $100 million to $200 million range, assuming regulatory approval and compendia listing. - Ameet Mallik, CEO

Q: How does the LOTIS-5 trial impact your strategy for LOTIS-7? A: LOTIS-5 and LOTIS-7 are complementary approaches addressing different patient needs. LOTIS-5 offers a non-systemic chemo combination with favorable safety and convenience, while LOTIS-7 aims to be the preferred bispecific combination in second-line plus DLBCL. Both approaches allow us to cater to patients who can't access or are not suitable for CAR-T or bispecific therapies. - Ameet Mallik, CEO

Q: What are the benchmarks for LOTIS-5 to be considered competitive in terms of efficacy and safety? A: For LOTIS-5, a complete response rate north of 40% would be differentiated. The study is powered to show a two-month difference in PFS compared to R-GemOx, which typically has a PFS of three to four months. We are encouraged by the safety run-in data showing an overall response rate of 80% and a complete response rate of 50%. - Ameet Mallik, CEO

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10